Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV004701146 | SCV005204700 | pathogenic | Hereditary factor VIII deficiency disease | 2024-06-18 | criteria provided, single submitter | clinical testing | Variant summary: The variant involves the duplication of exons 13 in the F8 gene. A presumed nomenclature of c.(1903+1_1904-1)_(2113+1_2114-1)dup has been designated for the purposes of this classification. It is assumed to be a tandem duplication in direct orientation (PMIDs: 25640679, 30054569). This Copy Number Variant (CNV) is predicted to result in an in-frame duplication within this gene. The variant was absent in 16079 control chromosomes. c.(1903+1_1904-1)_(2113+1_2114-1)dup has been reported in the literature in multiple individuals affected with Factor VIII Deficiency (Hemophilia A) (example, Murru _1990, Rost_2008, Casula_1990, Maura_2004). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 2159433, 18752578, 2105106, 15194549). No submitters have cited clinical-significance assessments for this variant to ClinVar. Based on the evidence outlined above, the variant was classified as pathogenic. |